Researchers predict a steady increase in fatty liver disease in the U.S. population, but there's not a lot of treatment ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A small clinical trial in China suggests that a low-dose vitamin E supplement could improve liver tissues and scarring for ...

Akero Therapeutics, 89bio, Boston Pharmaceuticals and more are working to bring novel treatment options for metabolic ...

Over the last year, 89bio’s stock has been somewhat volatile. Shares climbed past $10 earlier this year, but dropped under $6 ...

Data from a meta-analysis of 8 observational studies accounting for more than 26 million people across the globe were ...

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death worldwide. Multiple treatment modalities ...

Unlike liver disease linked to alcohol abuse, MASLD is driven largely by metabolic imbalances, poor diet and sedentary ...

89bio, Inc. is a clinical-stage biotech focused on liver and cardio-metabolic diseases, with its lead drug candidate ...

A recent review highlights the gaps in clinical guidelines and treatment approaches for metabolic dysfunction-associated ...

April 15, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage ...